1 Legha S,Benjamin RS,Mackay B,et al.Reduction of dsx-orubicin cardiotoxicity by prologed continuous iv infu-soion.Ann Intern Med,1982，96:133. 2 Rozencweig M.Anthracycline derivatives in new drug de-velopment programs.Cancer Treat Rep,1979，63:807. 3 Herman E.Redution of chronic doxorubicin cardiotoxicity in dogs by pretreatment with propane.Cancer Res,1981，41:3436. 4 Ryman BE,Tyrell DA.Liposome-bag of protential.Essays Biochem,1980，16:49. 5 Yatyin MB.Clinical prospects for liposome.Med Phys,1982，9(2):149. 6 Weinstein JN,Leserman LD.Liposome as drug carriers in cancer.Pharmaco Ther,1984，24:207. 7 Rahman A.Antitumor and toxicity evaluation of free dox-orubicin entrapped in cardiolipin liposomes,Cancer Chemother Pharmacol,1986，16:22. 8 Gabizon A,Goren D,Fuks Z,et al.Superior therapeutic activity of liposome associated adriamycin in a murine metastatic tumor model.Br J Cancer,1985，51:681. 9 Herman E,Rahman,A Ferrans V,et al.Prevention of chronic doxorubicin cardiotnoxiciyt in beagles by liposomal encapsulation.Carncer Res,1983，43:5427. 10 Gabizon A,Goren D,Fuks Z,et al.Enhanced of adri-amycin delivery of liver metastatic cells with increased tumorcidical effect using liposomes as drug carries,Cancer Res,1983，43:4730. 11 Rahman A,Treat J,Roe J,et al.A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorobicin.J Clin Oncol,1990，8:1093. 12 Treat J,Rahman A.Aphase I study:Liposmal encapsu-lated doxorubicin.J Cell Biochem(Suppl),1988，12B:252. 13 Gabizon A,Sulkes A,Benbaruch N.Exploratory clinical phase of liposoma encapsulated doxorubicin.Eur J Cancer Clin Oncol,1989，25:1795. 14 Treat J,Greenspan A,Forst D,et al.Antitumor acting of liposomeencapsulated doxorubicin in advanced breast can-cer;phase Ⅱ study.J Natl Cancer Inst,1990，82:1706. 15 Lohri A,Gelmon KA,Embree L,et al.Phase Ⅰ/Ⅱ study ofliposomal encapsulated doxorubicin(TLCD-99)in non small cell lung cancer.Proc Asco,1991，10:106. 16 Cowens J,Greaven P,Grelo W,et al.Initial clinical phase I trial of TLC D-99.Cancer Res,1993，53:2796. 17 Szoka JR.The future of liposomal drug delivery.Biotechn & Applied Biochem,1990，12:496. 18 YiYu ZOu,Makiko Y,Isama H,et al.Enhanced therapy iffect against liver 256 carcinosarcoma with temptures-senstive liposomal adriamycin adiminstration into the hep-atic artery.Caner Res,1993，53:3046. 19 Ozods R,Young RC,Speyer JL,et.Phase I and phar-macological studies of adramycin administered intraperi-toneally to patients with ovarian cancer,Cancer Res,1982，42:4265. 20 Rahman A,White G,More N,et al.Pharmacological,toxi-calogical and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes.Cancer Res,1985，45:796. 21 Parker RJ,Hartman KD,Sieber SM.Lymphatic node ad-sorbtion and tisues distribution of liposomal encapsulated[C]adriamycin following adminstrition in rat.Cancer Res,1981，41:1311. 22 Delgado S,Potkul P,Treat J,et al.Aphase Ⅰ/Ⅱ study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer.Am J Obstet Gynecol,1989，160:812. 23 Potkul Pk,Delgado G,Treat J,et al.Aphase Ⅰ/Ⅱ study of intraperitoneally administered liposome-encapsulated doxorubicin.Proc ASCD,1989，8:312. 24 Souhami L,Sljvic VS.The effect of reticuloendotheial blockade on the blood clearance and tissus distribution of liposomes.BBA,1980，6(9):1143. 25 Balaxsovits J,Mayer LD,Bally MB,et al.Analysis of the effect of liposome encapsulated on the vesicant properties acute cardioic toxicites and antitumor efficacy of doxoru-bicin.Cancer Chemother Pharmacol,1989，23:81. 26 Yoshimi A,Toshihisa Y,Isamu M,et al.Delivery of lymph nodetargeted adriamycin by gastric submucosal li-posomal injection in rabbits.Jan J Cancer Res,1993，84:208. 27 Konno H,Suzuki H,Tadakuma T,et al.Antitumor effect of adriamycin entrapped in lipsome conjugated with anti-human A-fetoprotein monoclonal antibody.Cancer Res,1987，47:4471.